Bombay HC directs Centre to decide representation seeking ‘compulsory licenses’ to two patented anti-TB drugs·March 10, 2021
Statement by Indian Civil Society: Need for open innovation and knowledge sharing for COVID-19 healthcare through Indian IP laws·June 24, 2020
Leaked Text Incorporates Stringent TRIPS Plus Elements, Global Calls for Rejection Increase·April 12, 2022
World TB Day coincides with the Indian Patent Office rejecting J&J’s application to extend its patent on anti-tuberculosis drug Bedaquiline·March 24, 2023
Dynamic injunction against rogue websites streaming Cricket World Cup by Delhi High Court·September 29, 2023
Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question?·October 8, 2020
Plea filed in SC seeking directions to Centre to issue compulsory licenses for patents on Remdesivir, Favipiravir, Tocilizumab·April 29, 2021